Donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) are associated with worse outcomes after lung transplantation. To determine the incidence and characteristics of DSA early after lung transplantation, we conducted a prospective multicenter observational study that used standardized treatment and testing protocols. Among 119 transplant recipients, 43 (36%) developed DSA: 6 (14%) developed DSA only to class I HLA, 23 (53%) developed DSA only to class II HLA, and 14 (33%) developed DSA to both class I and class II HLA. The median DSA mean fluorescence intensity (MFI) was 3197. We identified a significant association between the Lung Allocation Score and the development of DSA (HR = 1.02, 95% CI: 1.001-1.03, P = .047) and a significant association between DSA with an MFI ≥ 3000 and acute cellular rejection (ACR) grade ≥ A2 (HR = 2.11, 95% CI: 1.04-4.27, P = .039).
| INTRODUC TI ON
Lung transplantation may prolong survival and improve quality of life for patients who have advanced lung disease. [1] [2] [3] [4] [5] However, longterm outcomes after lung transplantation remain disappointing;
according to the latest International Society for Heart and Lung Transplantation (ISHLT) Registry report, recipients from the most recent era had a median survival of approximately 6 years. 6 The most common causes of death in the first year after transplantation are infection and allograft failure related to primary graft dysfunction (PGD), but allograft failure due to chronic lung allograft dysfunction (CLAD), including bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS), accounts for over 40% of deaths and remains the main obstacle to better long-term outcomes after transplantation.
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Conventional immunosuppression has primarily targeted T cell proliferation and function for the prevention of allograft rejection in solid-organ transplantation. However, evidence supporting a role for humoral immunity in allograft rejection has grown over time.
Hyperacute rejection due to preformed donor-specific antibodies (DSA) to mismatched human leukocyte antigens (HLA) has long been recognized as a cause of early allograft failure, and an association between HLA antibodies and CLAD has been recognized since the late 1990s. [11] [12] [13] [14] More recently, clinicians and investigators have better recognized antibody-mediated rejection (AMR) after lung transplantation, and an ISHLT working group has developed a consensus definition. [15] [16] [17] [18] [19] [20] In previous retrospective single-center studies, the incidence of DSA after lung transplantation has varied between 13% and 61%, and these studies have not used a standardized approach to testing and management. [21] [22] [23] [24] [25] [26] [27] [28] We sought to examine the incidence of DSA and their characteristics in a prospective multicenter study that used a standardized approach to clinical management, monitoring, and DSA testing.
| ME THODS

| Study design and eligibility criteria
We conducted a prospective observational cohort study of lung Local institutional review boards at each center approved the study protocol, and all participants provided written informed consent.
| Endpoints and outcomes
Primary and secondary endpoints were defined during protocol development. The study used HALT (HLA Antibodies after Lung Transplantation)-defined DSA (Table 1) as the primary endpoint, and the cumulative incidence of first DSA during the first 4 months after transplantation as the primary outcome. Protocol-defined secondary endpoints included antibody-mediated rejection (AMR), acute cellular rejection (ACR), lymphocytic bronchiolitis (LB), and death. ACR and LB were defined according to the standard ISHLT criteria. 29 However, for the diagnosis of AMR, we used a central blinded adjudication committee because the ISHLT definition was proposed after the study was completed. 20 As part of the secondary endpoints, we also examined the association between DSA and the development of ACR and LB.
HLA. DSA with an MFI ≥ 3000 have a significant association with ACR. Extended follow-up is necessary to determine the impact of DSA on other important outcomes.
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| HLA testing
Before transplantation, candidates underwent low resolution HLA-A, B, C, DRB1, DRB3, DRB4, DRB5, and DQB typing by the transplant center's histocompatibility laboratory using DNA-based methods. After transplantation, recipients were tested for DSA using the 
| Standardized clinical care
Prior to initiation of study enrollment, the sites agreed upon a standardized general clinical approach to induction and maintenance immunosuppression, infection prophylaxis, monitoring with pulmonary function testing (PFT) and bronchoscopy, and ACR treatment.
| Statistical analyses
The study used standard descriptive analyses for reporting. For comparisons of characteristics between subgroups, we used t tests (or Wilcoxon-Rank sum tests if the data were not normally distributed)
and chi-square (or Fisher's exact) tests. For the primary endpoint of the study (ie, posttransplant DSA), we used the Kaplan-Meier method to estimate time to DSA development. We used Cox proportional hazards regression to identify risk factors for the development of DSA and to assess for associations between the development of DSA and ACR and LB. We performed these analyses post hoc and did not adjust for multiple comparisons. In the analyses of risk factors for the development of DSA, we included only episodes of ACR and LB that occurred before DSA, and in the analyses of the impact of DSA on ACR and LB, we included only episodes of ACR and LB that occurred after DSA. We confirmed model assumptions and performed regression diagnostics, and censored for death, retransplant, end of study, and loss to follow-up. We used SPSS 22.0 (SAS, Inc., Chicago, IL) for all analyses. The online data supplement provides additional details on data management and power calculations.
| RE SULTS
During the enrollment period, study personnel prescreened 397 transplant candidates and recipients among the centers. Among the 397 potential participants, 227 (57%) were not transplanted during the study period. Of the 232 potentially eligible and consented patients, 126 underwent lung transplantation ( Figure 1 ). Of these, the study excluded 7 patients because of treatment with intravenous immune globulin (IVIG) or cytomegalovirus (CMV) immune globulin for hypogammaglobulinemia or high-risk CMV status. The remaining 119 lung transplant recipients comprised the primary HALT study cohort ( Figure 1 ). Only 51 of 397 (13%) potential participants were transplanted but not included in the study cohort. In general, study participants had similar demographics to contemporary US lung transplant recipients (Table 2) . During the 4 months of posttransplant follow-up, the cohort of lung transplant recipients had a first DSA cumulative incidence of 36% (43/119; 95% CI 28%-45%; Figure 2 ). There was no statistically significant difference in the incidence of DSA between the 6 sites (P = .119, Figure 3A) . DSA specificity for HLA-DQ was most frequent (n = 26, Figure 3B ). The median MFI of the (Table 4) . In separate analyses, we forced positive B cell crossmatch, the number of donorrecipient mismatches at the HLA-DR and HLA-DQ loci, LB, ACR, PGD grade, 31 age, and gender into the final model, but none of these covariates improved the model's -2 log likelihood or showed statistical significance (data not shown). In these models, the proportional hazards assumptions were met and we excluded nonlinearity using partial residual plots.
During the study period, 112 recipients had transbronchial lung biopsies for evaluation of ACR, and 7 did not because of various We did not detect a significant association between HALT-defined DSA and ACR (Table 5) . We examined associations between DSA and ACR using different DSA MFI thresholds and identified a trend to an increased risk of ACR grade ≥ A1 associated with DSA with an MFI ≥ 2000 and MFI ≥ 3000 and a statistically significant association between DSA with an MFI ≥ 3000 and ACR grade ≥ A2 (Table 5 ). Furthermore, we detected a significant association between the number of DSA specificities and ACR grade ≥ A2 (Table 5 ). We examined associations between DSA class and ACR and identified an increased risk of ACR grade ≥ A2 associated with DSA to both class I and class II HLA (Table 5) . We did not detect any significant associations between any definition of DSA and LB.
During the study period, 4 of the 43 (9%, 95% CI: 1%-18%) recipients who developed DSA developed AMR (Table 6 ). 
| D ISCUSS I ON
In this prospective multicenter study that utilized a standardized approach to patient management and DSA testing, we examined the incidence and characteristics of DSA after lung transplantation.
DSA developed frequently and early after transplantation, with an incidence of 36% in the first 4 months. The majority of DSA were directed at class II HLA, and a minority was directed solely at class I HLA. We identified higher LAS at transplant as an independent risk factor for the development of DSA. The early development of DSA, particularly in the first 2 weeks after transplantation, suggests a memory response though most patients did not have identifiable analysis pretransplant DSA was a significant risk factor for developing DSA after transplantation, it was no longer significant after adjusting for LAS. We detected an association between DSA with an MFI ≥ 3000 and ACR, though we did not detect a significant association between DSA with a lower MFI and ACR, and DSA had no significant impact on allograft survival. However, we note that the short follow-up period in this study limits our ability to fully characterize the impact of DSA on CLAD and allograft survival.
The cumulative incidence of DSA of 36% in this study is similar to previous single-center reports where the incidence ranged between 13% and 61%. [21] [22] [23] [24] [25] [26] [27] [28] Differences in the incidence of DSA among studies are likely related to different DSA testing protocols, DSA definitions, patient characteristics, and clinical regimens (eg, immunosuppression, blood product transfusion). We used a low threshold MFI to define DSA positivity in this study in an attempt to detect DSA early. Previous studies have consistently shown an association between DSA and adverse clinical outcomes after lung transplantation, and we reasoned that early detection would identify patients at increased risk for ACR, LB, CLAD, and allograft failure. Model chi-square = 6.83, -2 log likelihood = 371.02, P = .033.
longer duration of follow-up is necessary to identify the MFI threshold that may be associated with the development of CLAD. Although with the risk of cellular rejection. We did not identify a significant association between DSA to class II HLA and ACR as described in some previous studies, likely because of the relatively small sample size. In contrast, we did find an association between DSA and both class I and class II HLA and an increased risk of ACR, and we suspect the number of DSA specificities drove this relationship.
The study protocol did not include antibody-directed therapy after DSA identification because this remains controversial.
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Although retrospective cohort studies have suggested that treatment of asymptomatic DSA may improve clinical outcomes, the optimal regimen is unknown and spontaneous DSA clearance may occur. 27, 28, 34, 35 Thus, we propose that the efficacy and safety of treatment for asymptomatic DSA should be investigated in the context of a randomized controlled trial.
In contrast to previous studies, we did not identify an association between PGD and DSA. 36, 37 However, the cohort had a small number of patients who developed PGD grade 2 or grade 3, and the study did not have sufficient power to detect a small but potentially important association. Nevertheless, our findings demonstrate a significant association between the LAS at transplant and DSA development. This is consistent with a recent study that reported a more than 2-fold higher risk of DSA among patients with an LAS > 60. 28 The LAS reflects severity of illness before transplantation, and a higher LAS is associated with increased morbidity that includes PGD, acute kidney injury, infections, respiratory failure, and prolonged critical illness early after transplantation. a significant number of patients developed DSA beyond the first year after transplantation in other studies. 23, 24, 27 In addition, the short follow-up did not allow an appropriate assessment of the impact of DSA on CLAD and survival. The study duration also likely underestimated the incidence of AMR. Furthermore, the short follow-up duration limited our ability to assess the frequency of DSA persistence, resolution, recurrence, MFI changes, and profile switching. The study sample size influenced the precision of our estimates of the cumulative incidence of first DSA, though the 95% CI (28%-45%) suggests that DSA occur commonly. The small sample size likely also affected our ability to identify risk factors for DSA development. Lastly, we did not validate antibody testing results in a separate or core laboratory.
We conclude that DSA occur commonly early after lung transplantation and that DSA are more frequently directed at class II HLA.
We strongly support the move toward standardized DSA testing and reporting. 42 Future studies should further clarify the association between DSA and long-term outcomes after lung transplantation and the potential role of preemptive antibody-directed therapy for transplant recipients who develop DSA. TA B L E 6 Clinical presentation and diagnostic certainty of cases of suspected antibody-mediated rejection (AMR) 
